Pharmacotherapeutic perspectives on nutraceuticals in the treatment of MASLD and MASH.
作者信息
Eid Ali H, Khachab Maha, Kobeissy Firas, Sahebkar Amirhossein
机构信息
Department of Basic Medical Sciences, College of Medicine, QU Health, Qatar University, Doha, Qatar.
Department of Biomedical Sciences, Faculty of Medicine and Medical Sciences, University of Balamand, Beirut, Lebanon.
出版信息
Ther Adv Chronic Dis. 2025 May 24;16:20406223251339388. doi: 10.1177/20406223251339388. eCollection 2025.
Abstract
摘要
相似文献
1
Pharmacotherapeutic perspectives on nutraceuticals in the treatment of MASLD and MASH.营养保健品在治疗非酒精性脂肪性肝炎和非酒精性脂肪性肝炎相关肝硬化中的药物治疗前景。
Ther Adv Chronic Dis. 2025 May 24;16:20406223251339388. doi: 10.1177/20406223251339388. eCollection 2025.
2
Can Nutraceuticals Support the Treatment of MASLD/MASH, and thus Affect the Process of Liver Fibrosis?营养保健品能否支持 MASLD/MASH 的治疗，从而影响肝纤维化的进程？
Int J Mol Sci. 2024 May 11;25(10):5238. doi: 10.3390/ijms25105238.
3
NAFLD (MASLD)/NASH (MASH): Does It Bother to Label at All? A Comprehensive Narrative Review.非酒精性脂肪性肝病（MASLD）/非酒精性脂肪性肝炎（MASH）：是否有必要进行标记？全面的叙述性综述。
Int J Mol Sci. 2024 Aug 2;25(15):8462. doi: 10.3390/ijms25158462.
4
Nutraceutical Approach to Non-Alcoholic Fatty Liver Disease (NAFLD): The Available Clinical Evidence.营养疗法治疗非酒精性脂肪性肝病（NAFLD）：现有临床证据。
Nutrients. 2018 Aug 23;10(9):1153. doi: 10.3390/nu10091153.
5
Probiotic Mixture Ameliorates a Diet-Induced MASLD/MASH Murine Model through the Regulation of Hepatic Lipid Metabolism and the Gut Microbiome.益生菌混合物通过调节肝脂代谢和肠道微生物群改善饮食诱导的 MASLD/MASH 小鼠模型。
J Agric Food Chem. 2024 Apr 17;72(15):8536-8549. doi: 10.1021/acs.jafc.3c08910. Epub 2024 Apr 4.
6
Systemic impacts of metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) on heart, muscle, and kidney related diseases.代谢功能障碍相关脂肪性肝病（MASLD）和代谢功能障碍相关脂肪性肝炎（MASH）对心脏、肌肉和肾脏相关疾病的全身影响。
Front Cell Dev Biol. 2024 Jul 16;12:1433857. doi: 10.3389/fcell.2024.1433857. eCollection 2024.
7
Manifestation and Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease in a Predominately African American Population at a Multi-Specialty Healthcare Organization.在一家多专科医疗保健机构中，以非裔美国人为主的人群中代谢功能障碍相关脂肪性肝病的表现与进展
Healthcare (Basel). 2024 Jul 25;12(15):1478. doi: 10.3390/healthcare12151478.
8
Incretin-based investigational therapies for the treatment of MASLD/MASH.基于肠降血糖素的治疗 MASLD/MASH 的研究性疗法。
Diabetes Res Clin Pract. 2024 May;211:111675. doi: 10.1016/j.diabres.2024.111675. Epub 2024 Apr 16.
9
Impact of Weight Loss on Metabolic Dysfunction Associated Steatohepatitis and Hepatic Fibrosis.体重减轻对代谢功能障碍相关脂肪性肝炎和肝纤维化的影响。
Curr Diab Rep. 2025 Feb 18;25(1):23. doi: 10.1007/s11892-025-01579-1.
10
Molecular Mechanisms of Curcumin in the Pathogenesis of Metabolic Dysfunction Associated Steatotic Liver Disease.姜黄素在代谢功能障碍相关脂肪性肝病发病机制中的分子机制。
Nutrients. 2023 Dec 9;15(24):5053. doi: 10.3390/nu15245053.
本文引用的文献
1
Flavonoids, gut microbiota and cardiovascular disease: Dynamics and interplay.类黄酮、肠道微生物群与心血管疾病：动态与相互作用。
Pharmacol Res. 2024 Nov;209:107452. doi: 10.1016/j.phrs.2024.107452. Epub 2024 Oct 8.
2
Effectiveness of Omega-3 Polyunsaturated Fatty Acids in Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis.ω-3多不饱和脂肪酸在非酒精性脂肪性肝病中的有效性：一项系统评价和荟萃分析
Cureus. 2024 Aug 28;16(8):e68002. doi: 10.7759/cureus.68002. eCollection 2024 Aug.
3
The role of dietary modification in the prevention and management of metabolic dysfunction-associated fatty liver disease: An international multidisciplinary expert consensus.饮食调整在代谢相关脂肪性肝病防治中的作用：国际多学科专家共识。
Metabolism. 2024 Dec;161:156028. doi: 10.1016/j.metabol.2024.156028. Epub 2024 Sep 11.
4
Curcumin-primed olfactory mucosa-derived mesenchymal stem cells mitigate cerebral ischemia/reperfusion injury-induced neuronal PANoptosis by modulating microglial polarization.姜黄素预刺激嗅黏膜来源的间充质干细胞通过调节小胶质细胞极化减轻脑缺血/再灌注损伤诱导的神经元 PANoptosis。
Phytomedicine. 2024 Jul;129:155635. doi: 10.1016/j.phymed.2024.155635. Epub 2024 Apr 20.
5
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.一项评估 Resmetirom 治疗伴有肝纤维化的 NASH 的 3 期随机对照试验。
N Engl J Med. 2024 Feb 8;390(6):497-509. doi: 10.1056/NEJMoa2309000.
6
Curcumin supplementation effect on liver enzymes in patients with nonalcoholic fatty liver disease: a GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials.姜黄素补充剂对非酒精性脂肪性肝病患者肝酶的影响：一项采用GRADE评估的随机对照试验系统评价和剂量反应荟萃分析
Nutr Rev. 2025 Jan 1;83(1):1-12. doi: 10.1093/nutrit/nuad166.
7
Use of probiotics, prebiotics, and synbiotics in non-alcoholic fatty liver disease: A systematic review and meta-analysis.益生菌、益生元及合生元在非酒精性脂肪性肝病中的应用：一项系统评价与荟萃分析
J Gastroenterol Hepatol. 2023 Oct;38(10):1682-1694. doi: 10.1111/jgh.16256. Epub 2023 Jul 6.
8
Curcumae rhizoma and its major constituents against hepatobiliary disease: Pharmacotherapeutic properties and potential clinical applications.莪术及其主要成分抗肝胆疾病的作用：药理作用及潜在临床应用。
Phytomedicine. 2022 Jul 20;102:154090. doi: 10.1016/j.phymed.2022.154090. Epub 2022 Mar 31.
9
Impact of Long-Term Supplementation with Fish Oil in Individuals with Non-Alcoholic Fatty Liver Disease: A Double Blind Randomized Placebo Controlled Clinical Trial.长期补充鱼油对非酒精性脂肪性肝病患者的影响：一项双盲随机安慰剂对照临床试验。
Nutrients. 2020 Nov 2;12(11):3372. doi: 10.3390/nu12113372.
10
Effects of curcuminoids on inflammatory status in patients with non-alcoholic fatty liver disease: A randomized controlled trial.姜黄素类对非酒精性脂肪性肝病患者炎症状态的影响：一项随机对照试验。
Complement Ther Med. 2020 Mar;49:102322. doi: 10.1016/j.ctim.2020.102322. Epub 2020 Jan 21.
Zotero 插件